Kesimpta Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to limitations of traditional ms therapies, increasing ms diagnosis rates, advances in monoclonal antibody science, neurologist adoption of b cell targeting, demand for convenient dosing.

The growth in the forecast period can be attributed to growing relapsing ms population, increased home injection adoption, expansion into progressive ms forms, improved patient adherence, rising neurology healthcare investment. Major trends in the forecast period include shift toward b cell depleting therapies, preference for self administered ms treatments, growth in early ms intervention, rising use of targeted immunotherapies, expansion of home based neurology care.

The rising prevalence of multiple sclerosis (MS) is expected to drive the growth of the kesimpta market in the future. Multiple sclerosis (MS) is a chronic autoimmune condition that impacts the central nervous system, leading to nerve fiber degeneration and resulting in symptoms such as muscle weakness, vision issues, and cognitive decline. The growing prevalence of MS can be attributed to various factors, including advancements in diagnostics, increased awareness, and improved reporting mechanisms. Kesimpta is utilized to treat relapsing forms of multiple sclerosis (MS) by targeting B-cells to reduce relapses and slow down disability progression. For example, a study published in August 2025 in Neurologia i Neurochirurgia Polska, a peer-reviewed medical journal from Poland, highlighted that MS incidence is on the rise in China, with estimates ranging from 0.2 to 0.6 per 100,000 people annually. In Turkey, the MS incidence rate in 2022 was 6.2 per 100,000, and in Saudi Arabia, MS incidence is also increasing, with estimates indicating rates between 3 and 5 per 100,000 annually. As a result, the growing prevalence of MS is driving the expansion of the kesimpta market.

The growth of the kesimpta market is also expected to be accelerated by the rise in healthcare expenditure. Healthcare expenditure encompasses total spending on services like hospital care, medical research, pharmaceuticals, public health programs, and other related areas. Several factors contribute to the increase in healthcare spending, including an aging population, a higher prevalence of chronic diseases, technological advancements in medicine, and rising treatment costs. Healthcare expenditure for Kesimpta is focused on improving patient outcomes by reducing disease relapses and progression. For instance, in May 2024, a report from the Office for National Statistics, a UK-based government agency, revealed that total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, compared to a growth rate of 0.9% in 2022. Additionally, long-term health and social care expenditure increased by 2.8% in real terms in 2022. Consequently, the increase in healthcare spending is driving the expansion of the kesimpta market.

A key trend in the kesimpta market is the growing adoption of self-administered, targeted B-cell therapy for treating relapsing forms of multiple sclerosis (RMS). Kesimpta's self-administered, targeted B-cell therapy offers an effective and convenient treatment solution for RMS, helping to reduce relapses and slow disease progression. For example, in April 2024, Novartis AG, a pharmaceutical company based in Switzerland, released six-year efficacy data for Kesimpta (ofatumumab), showing substantial benefits for individuals with recently diagnosed, treatment-naïve relapsing multiple sclerosis (RMS). This data, derived from the ALITHIOS open-label extension study, emphasizes the significance of early intervention in managing this chronic disease.

Major companies operating in the kesimpta market are Novartis AG.

North America was the largest region in the kesimpta market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kesimpta market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the kesimpta market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the kesimpta market by increasing costs for monoclonal antibody manufacturing materials and autoinjector components. Neurology clinics and specialty pharmacies in europe and north america are most affected due to biologic import reliance. These tariffs may impact pricing and reimbursement dynamics. However, tariffs are supporting regional biologics manufacturing and enhancing localized supply chain resilience for ms therapies.

The kesimpta market research report is one of a series of new reports that provides kesimpta market statistics, including kesimpta industry global market size, regional shares, competitors with a kesimpta market share, detailed kesimpta market segments, market trends and opportunities, and any further data you may need to thrive in the kesimpta industry. This kesimpta market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Kesimpta (ofatumumab) is a prescription medication classified as a monoclonal antibody used to treat relapsing forms of multiple sclerosis (MS) in adults. It works by targeting and depleting B-cells, which play a critical role in the immune system's attack on the nervous system in MS. Administered as a subcutaneous injection, Kesimpta offers a more convenient alternative compared to intravenous therapies. While generally well-tolerated, potential side effects of Kesimpta include infections, headache, and injection site reactions.

The main indications for Kesimpta include the treatment of multiple sclerosis (MS), specifically relapsing forms such as relapsing-remitting multiple sclerosis (RRMS), clinically isolated syndrome (CIS), and active secondary progressive multiple sclerosis (SPMS). The treatment of multiple sclerosis with Kesimpta helps reduce disease activity by depleting B-cells that contribute to the progression of MS. The formulations are injectable, available in pre-filled syringes or autoinjectors, and are suitable for a wide range of patient demographics, including pediatric, adult, and geriatric patients. Kesimpta is distributed through various channels, including direct sales, wholesalers and distributors, retail pharmacies, and online pharmacies. It is used by a variety of end users such as hospitals, specialty pharmacies, home healthcare providers, and neurology clinics.

The kesimpta market consists of sales of prefilled syringes, injection forms, and liquid solutions. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.